Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma

Table 1 Patient characteristics n (%)

	Neoadjuvant chemoradiotherapy(n = 12)1	Non-neoadjuvant chemoradiotherapy (n = 45)1	P value2
Demographic variables
Age (yr)	59.0 (48.25, 62.75)	67.0 (60.00, 69.00)	0.02
Age ≥ 60	6 (50.0)	35 (77.8)	0.08
Sex (Male)	8 (66.7)	24 (53.3)	0.41
Follow-up duration (mo)	31.9 (19.8, 53.8)	26.4 (14.5, 42.1)	0.27
Laboratory variables
Albumin (g/dL)	3.75 (3.450, 4.075)	3.60 (3.200, 3.850)	0.32
Total bilirubin (mg/dL)	2.3 (0.60, 8.45)	6.4 (2.35, 11.40)	< 0.05
CA 19-9 (U/mL)	181.8 (27.08, 1452.50)	210.0 (71.35, 976.00)	0.74
Cancer-related variables
Bismuth classification
IIIA	2 (16.7)	21 (46.7)	0.10
IIIB	3 (25.0)	2 (4.4)	0.06
IV	7 (58.3)	22 (48.9)	0.56
Pre-op AJCC 7th stage
IIIA (T3N0M0)	8 (66.7)	23 (51.1)	0.34
IIIB (T1-3N1M0)	2 (16.7)	17 (37.8)	0.30
IVA (T4N0-1M0)	1 (8.3)	3 (6.7)	> 0.99
IVB (T1-4N2M0)	1 (8.3)	2 (4.4)	0.52
Tumor differentiation			< 0.01
Well	0 (0)	11 (24.4)
Moderately	7 (58.3)	29 (64.4)
Poorly	0 (0)	5 (11.1)
Undetermined	5 (41.7)	0 (0)
Post-operative adjuvant treatment	5 (41.7)	27 (60.0)	0.26
Recurrence	10 (83.3)	31 (68.9)	0.48
OP site	3 (30.0)	11 (35.5)
Liver	2 (20.0)	3 (9.7)
Distant organ	3 (30.0)	9 (29.0)
Carcinomatosis	2 (20.0)	8 (25.8)

¹Continuous variables were denoted median (Q1, Q3) and categorical variables were denoted number (%);

²P values were determined using a Mann-Whitney test for continuous variables and a χ² test (Fisher’s exact test, Pearson and Mantel-Haenszel χ² test) for categorical variables. CA19-9: Carbohydrate antigen 19-9; AJCC: American Joint Committee on Cancer.